## Table of Contents

### Highlights of This Issue 3359

### SPECIAL FEATURES

#### CCR Translations

3361  MET as a Target in Papillary Renal Cell Carcinoma  
André P. Fay, Sabina Signoretti, and Toni K. Choueiri  
See related article, p. 3411

#### CCR Perspectives in Drug Approval

3364  U.S. Food and Drug Administration Inspections of Clinical Investigators: Overview of Results from 1977 to 2009  
Sonia K. Morgan-Linnell, David J. Stewart, and Razelle Kurzrock

#### Statistics in Clinical Cancer Research

3371  Blocking and Randomization to Improve Molecular Biomarker Discovery  
Li-Xuan Qin, Qin Zhou, Faina Bogomolniy, Liliana Villafania, Narciso Olvera, Magali Cavatore, Jaya M. Satagopan, Colin B. Begg, and Douglas A. Levine

#### Molecular Pathways

3379  Molecular Pathways: CDK4 Inhibitors for Cancer Therapy  
Mark A. Dickson

3384  Molecular Pathways: Niches in Metastatic Dormancy  
Kenji Yumoto, Matthew R. Eber, Janice E. Berry, Russell S. Taichman, and Yusuke Shiozawa

#### Review

3390  Infusions of Allogeneic Natural Killer Cells as Cancer Therapy  
Wing Leung

### HUMAN CANCER BIOLOGY

3401  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions  
Yong-Chen Lu, Xin Yao, Jessica S. Crystal, Yong F. Li, Mona El-Gamil, Colin Gross, Lindy Davis, Mark E. Dudley, James C. Yang, Yardena Samuels, Steven A. Rosenberg, and Paul F. Robbins

3411  MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array  
Laurence Albiges, Justine Guegan, Audrey Le Formal, Virginie Verkarre, Nathalie Rioux-Leclercq, Mathilde Sibony, Jean-Christophe Bernhard, Philippe Camparo, Zahra Merabet, Vincent Molinie, Yves Allory, Cedric Orear, Sophie Couvé, Sophie Gad, Jean-Jacques Patard, and Bernard Escudier  
See related article, p. 3361

3422  Prevailing Role of Contact Guidance in Intrastromal T-cell Trapping in Human Pancreatic Cancer  
Natalie Hartmann, Nathalia A. Giese, Thomas Giese, Isabel Poschke, Rienk Oftringa, Jens Werner, and Eduard Ryschich

3434  Overexpression of Sirt7 Exhibits Oncogenic Property and Serves as a Prognostic Factor in Colorectal Cancer  
Hongyan Yu, Wen Ye, Jiangxue Wu, Xiangqi Meng, Ran-yi Liu, Xiaofang Ying, Yi Zhou, Hui Wang, Changchuan Pan, and Wenlin Huang

### CANCER THERAPY: PRECLINICAL

3446  Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma  
Mohammad Atefi, Earl Avramis, Amanda Lassen, Deborah J.L. Wong, Lidia Robert, David Foulad, Michael Cermiglia, Bjorn Titz, Thinle Chodon, Thomas G. Graeber, Begonya Comin-Andux, and Antoni Ribas
### Table of Contents

#### 3458 Disruption of Follicular Dendritic Cells—Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)

#### 3472 Regorafenib Inhibits Colorectal Tumor Growth through PUMA-Mediated Apoptosis
- Dongshi Chen, Liang Wei, Jian Yu, and Lin Zhang

#### 3477 Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells
- Sae-Kyung Lee, Jyh Y. Chwee, Cheryl A.P. Ma, Nina Le Bert, Caleb W. Huang, and Stephan Gasser

#### 3486 Importance of EGFR/ERCC1 Interaction Following Radiation-Induced DNA Damage
- Giannaria Liccardi, John A. Hartley, and Daniel Hochhauser

#### 3487 Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT

#### 3492 Old Drug New Use—Amoxapine and Its Metabolites as Potent Bacterial β-Glucuronidase Inhibitors for Alleviating Cancer Drug Toxicity
- Ren Kong, Timothy Liu, Xiaoping Zhu, Syed Ahmad, Alfred L. Williams, Alexandrina T. Phan, Hong Zhao, John E. Scott, Li-An Yeh, and Stephen T.C. Wong

### IMAGING, DIAGNOSIS, PROGNOSIS

#### 3519 In Vivo Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment
- Yasaman Ardestirpour, Victor Chernomordik, Moinuddin Hassan, Rafal Zielinski, Jacek Capala, and Amir Gajdusek

#### 3530 Improved Differentiation of Benign and Malignant Breast Tumors with Multiparametric 18Fluorodeoxyglucose Positron Emission Tomography Magnetic Resonance Imaging: A Feasibility Study
- Katja Pinker, Wolfgang Bogner, Pascal Baltzer, Georgios Karanikas, Heinrich Magometschnigg, Peter Brader, Stephan Gruber, Hubert Bickel, Peter Dubsky, ZsuZsanna Bago-Horváth, Rupert Bartsh, Michael Weber, Siegfried Trattnig, and Thomas H. Helbich

#### 3550 Treatment Response Evaluation Using 18F-FDOPA PET in Patients with Recurrent Malignant Glioma on Bevacizumab Therapy
- Johannes Schwarzenberg, Johannes Czernin, Whitney B. Pope, Tristan Grogan, David Elashoff, Cheri Geist, Daniel H.S. Silverman, Michael E. Phelps, and Wei Chen

#### 3560 Variability in Assessing Treatment Response: Metastatic Colorectal Cancer as a Paradigm
- Binsheng Zhao, Shing M. Lee, Hyun-Ju Lee, Yong-Jang Tan, Jing Qi, Thorsten Persigehl, David P. Mozley, and Lawrence H. Schwartz

#### 3569 TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
- Laxmi Silwal-Pandit, Hans Kristian Moen Vollan, Suet-Feung Chin, Oscar M. Rueda, Steven McKinney, Tomo Osako, David A. Quigley, Vessela N. Kristensen, Samuel Aparicio, Anne-Lise Borresen-Dale, Carlos Caldas, and Anita Langerød

### CANCER THERAPY: CLINICAL

#### 3581 A Phase I Trial of LY2510924, a CXCR4 Peptide Antagonist, in Patients with Advanced Cancer
- Matthew D. Galsky, Nicholas J. Vogelzang, Paul Conkling, Eyas Raddad, John Polzer, Stephanie Roberson, John R. Stille, Mansoor Saleh, and Donald Thornton

#### 3589 Identification of Campath-1 (CD52) as Novel Drug Target in Neoplastic Stem Cells in 5q-Patients with MDS and AML
- Katharina Blatt, Harald Herrmann, Gregor Hoermann, Michael Willmann, Sabine Cerny-Reiterer, Irina Sadovnik, Susanne Hermihofener, Berthold Streubel, Werner Rabitsch, Wolfgang R. Speer, Matthias Mayerhofer, Thomas Külke, and Peter Valent
3603  Phase II Study of Cedirani in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, and Michael Leahy

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

3613  Prognostic and Therapeutic Implications of Aromatase Expression in Lung Adenocarcinomas with EGFR Mutations
Mikihiro Kohno, Tatsuro Okamoto, Kenichi Suda, Mototsugu Shimokawa, Hirokazu Kitahara, Shinichiro Shimamatsu, Hideyuki Konishi, Tsukihisa Yoshida, Mitsuhiko Takenoyama, Tokuiro Yano, and Yoshihiko Maehara

LETTERS TO THE EDITOR

3623  SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Letter
Abolfazl Avan, Mina Maftouh, Amir Avan, Carmelo Tibaldi, Paolo A. Zucali, and Elisa Giovannetti

3625  SNPs in PI3K-PTEN-mTOR and Brain Metastases in NSCLC—Response
Qianxia Li, Huihua Xiong, and Xianglin Yuan

ABOUT THE COVER

Loss of S6 phosphorylation as a biomarker of response to PI3K/mTOR pathway inhibition. The representative image shows immunohistochemical staining for phosphorylated S6 protein (ser235-236) in SUM190 breast cancer cell line xenografts treated with the pan-PI3K inhibitor BKM120. For details, see the article by O’Brien and colleagues on page 3507 of this issue.